Litzman supports medical marijuana export
Teva to become exclusive marketer, distributor of medical cannabis inhaler in IsraelTeva Pharmaceuticals and Syqe Medical reached an agreement according to which the multinational pharmaceutical giant will be the exclusive marketer and distributor of an inhaler for medical cannabis in Israel. “Teva Israel is entering the field of medical cannabis out of a deep commitment to patients dealing with pain,” said the Teva Israel CEO.
Israel's Teva Pharmaceuticals announced today (Monday) that it will begin to market a medical cannabis inhaler, which is manufactured by the Israeli company Syqe Medical.
“This is the first inhaler that allows the provision of the plant in accordance with the safety and exact levels of a prescription,” said Teva Pharmaceuticals in a statement. “It is expected to meet the emerging requirements of the Israeli Health Ministry.”
The cooperation between Teva Pharmaceuticals and Syqe Medical in the domain of pain management led to the marketing agreement. According to the agreement, Teva Pharmaceuticals will be the exclusive marketer and distributor of the inhaler. “This is the first time that the field of medical cannabis meets the standards for the provision of pharmaceutical inhalation,” added Teva Pharmaceuticals.
The inhaler is already being used in Haifa’s Rambam Hospital under the Israeli Health Ministry’s approval. The new deal seeks to allow patients to consume medical cannabis from the comfort of their own home.
“Teva Israel is entering the field of medical cannabis out of a deep commitment to patients dealing with pain, which is one of the company’s core focal points,” said Teva Israel CEO Avinoam Sapir.
Found mistakes in this report? - Click Here